Aplidin (plitidepsin)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors. The specific marine organism is Aplidium albicans.
Clinical Trials:
For a list of clinical trials studying Aplidin for the treatment of multiple myeloma, see ClinicalTrials.gov.
Information about Aplidin also is available at the PharmaMar website.
Source: Wikipedia article about Aplidin (as of November 14, 2009).
Related Articles:
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Getting To Know: TNB-383B
- Getting To Know: Tiragolumab
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
